Where we at?, page-42

First 42 Last

Share
Profile

Follow
Gan_Gans

2,143 Posts.

576

06/04/24

11:59

Post #: 73219022
Share

Originally posted by 39KP: ↑

I get it that no news + low cash + shares at 33c cause concern. but why are people saying that we are going bust in 6 weeks ?

they are getting a peer review as promised

they are trying to get the dose approved

they are trying to sort funding.

they are speaking to partners

given they have lots of data to show the fda (is this a bad thing ?) the fda have asked for a different pathway and will revert in June hopefully.

if people expect daily updates they are mistaken. if you think shares going down when Nasdaq / S&P have the worst day in 6 months is cause for concern then ok, but I don't see what it has to do with par or any other small cap I own.

is any big fund buying bc we are at 10% of our highs ? no. they are professionals and don't take punts. they will wait for the fda decision/ tga / peer review / breakthrough or whatever is coming down the pipe.

I am not saying all is well and this stock is going to the moon. I am just saying let's focus on the fact that they are discussing right now with the fda etc. if we don't get 2x2 and if we can't get cash etc then I will probably sell too. but am I selling because simon and Paul are not telling us regularly exactly what they are up to ? no

it seems this forum is either high as a kite or near suicidal.

everyone says these guys are incompetent etc etc etc. Apple just shut down their car project after 5+ years and billions of dollars. sometimes it doesn't work out. even for the best.

par is taking longer than we all hoped. are they morons ? I don't know, is Tim Cook a moron ? I say no.

I could go on but if you don't like the quiet periods / if u don't like management/ If u think they are going bust then sell.

why anyone would stay invested and spend time on HC if they think a company has 60/90 days to survive is beyond me

Expand

39KP,

what is this about FDA reverting in June and the FDA asking for a different pathway?

PAR Price at posting: 33.0¢ Sentiment: None Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 665 more messages in this thread...

First 42 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change 0.000(0.00%)		Mkt cap ! $71.79M

Open	High	Low	Value	Volume
20.0¢	20.5¢	19.5¢	$216.0K	1.078M

Buyers (Bids)

No.	Vol.	Price($)
2	6309	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	63209	5

View Market Depth

No.	Vol.	Price($)
1	14057	0.225
1	1749	0.200
6	500189	0.195
21	293713	0.190
4	145320	0.185

Price($)	Vol.	No.
0.180	26	1
0.195	11598	1
0.205	2432	1
0.210	63209	5
0.215	98902	2

Last trade - 16.10pm 07/10/2024 (20 minute delay)

PAR (ASX) Chart

Where we at?, page-42

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where we at?, page-42

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News